Our study shows that, across the EF spectrum, at baseline, only 70% of patients were taking beta-blockers, 55% were taking renin–angiotensin system inhibitors, 12% were taking mineralocorticoid receptor antagonists, and 9% were taking SGLT2is (our study period was prior to the first approval of SGLT2is for HF in the European Union). Here, NR3C2 is linked to hydrops fetalis.